Received Feb 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
my father-in- died two days after they received the vaccine; This serious case was reported by a consumer via interactive digital media and described the occurrence of death in a male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, 2 days after receiving Arexvy, the patient experienced death (Verbatim: my father-in- died two days after they received the vaccine) (serious criteria death and GSK medically significant). The reported cause of death was death. It was unknown if the reporter considered the death to be related to Arexvy. The company considered the death to be unrelated to Arexvy. Additional Information: GSK Receipt Date: 03-FEB-2026 This case was reported by the daughter/ son of patient via interactive digital media. The reporter did not believe anything about the man-made COVID-19 virus. He/she believed it had been used as a genocide against our older people. The reporter's father-in law had died two days after he had received the vaccine, and reporter believed that millions more had been included in this. The batch number was not provided, and we are unable to contact the reporter. The case has been linked with case US2026AMR017434 reported by same reporter.; Sender's Comments: A case of Death, 2 days after receiving Arexvy, in a male patient. Based on the available information, a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow up has not been received. US-GSK-US2026AMR017434:same reporter; Reported Cause(s) of Death: Death